| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;111:90-96.)
© 2005 American Heart Association, Inc.
Molecular Cardiology |
From the Department of Emergency Medicine (H.-R.L., A.H., L.T., Y.Q., T.A.C., B.L.L., X.L.M.), Thomas Jefferson University, Philadelphia, Pa; the Center for Translational Medicine (E.G., P.M., W.J.K.), Thomas Jefferson University, Philadelphia, Pa; the Center for Apoptosis Research (E.S.A.), Kimmel Cancer Institute, Thomas Jefferson University, Philadelphia, Pa; and the Biomolecular Science Center and Department of Molecular Biology and Microbiology (A.S.Z.), University of Central Florida, Orlando, Fla.
Correspondence to Xin L. Ma, MD, PhD, Department of Emergency Medicine, Jefferson Medical College, 1020 Sansom St, Philadelphia, PA 19107-5004 (e-mail Xin.Ma{at}jefferson.edu); or Hui-Rong Liu, MD, PhD, Department of Physiology, Shangxi Medical University, Taiyuan, Shangxi, PR China (e-mail liuhr2000@hotmail.com).
Received August 9, 2004; revision received September 21, 2004; accepted September 30, 2004.
Background Omi/HtrA2 is a proapoptotic mitochondrial serine protease involved in caspase-dependent as well as caspase-independent cell death. However, the role of Omi/HtrA2 in the apoptotic cell death that occurs in vivo under pathological conditions remains unknown. The present study was designed to investigate whether Omi/HtrA2 plays an important role in postischemic myocardial apoptosis.
Methods and Results Male adult mice were subjected to 30 minutes of myocardial ischemia followed by reperfusion and treated with vehicle or ucf-101, a novel and specific Omi/HtrA2 inhibitor, 10 minutes before reperfusion. Myocardial ischemia/reperfusion significantly increased cytosolic Omi/HtrA2 content and markedly increased apoptosis. Treatment with ucf-101 exerted significant cardioprotective effects, as evidenced by less terminal dUTP nick end-labeling staining, a lower incidence of DNA ladder fragmentation, and smaller infarct size. Furthermore, treatment with ucf-101 before reperfusion attenuated X-linked inhibitor of apoptosis protein degradation and inhibited caspase-9 and caspase-3 activities.
Conclusion Taken together, these results demonstrate for the first time that ischemia/reperfusion results in Omi/HtrA2 translocation from the mitochondria to the cytosol, where it promotes cardiomyocyte apoptosis via a protease activitydependent, caspase-mediated pathway.
Key Words: apoptosis myocardial infarction reperfusion
This article has been cited by other articles:
![]() |
Q. Li, J. Li, and J. Ren UCF-101 mitigates streptozotocin-induced cardiomyocyte dysfunction: role of AMPK Am J Physiol Endocrinol Metab, October 1, 2009; 297(4): E965 - E973. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Ding, M. Patel, D. Shen, A. A. Herzlich, X. Cao, R. Villasmil, K. Klupsch, J. Tuo, J. Downward, and C.-C. Chan Enhanced HtrA2/Omi Expression in Oxidative Injury to Retinal Pigment Epithelial Cells and Murine Models of Neurodegeneration Invest. Ophthalmol. Vis. Sci., October 1, 2009; 50(10): 4957 - 4966. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Li, L. K. Hueckstaedt, and J. Ren The protease inhibitor UCF-101 ameliorates streptozotocin-induced mouse cardiomyocyte contractile dysfunction in vitro: role of AMP-activated protein kinase Exp Physiol, September 1, 2009; 94(9): 984 - 994. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Choudhury, S. Bae, S. R. Kumar, Q. Ke, B. Yalamarti, J. H. Choi, L. A. Kirshenbaum, and P. M. Kang Role of AIF in cardiac apoptosis in hypertrophic cardiomyocytes from Dahl salt-sensitive rats Cardiovasc Res, August 14, 2009; (2009) cvp261v2. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Balakrishnan, L. Cilenti, Z. Mashak, P. Popat, E. S. Alnemri, and A. S. Zervos THAP5 is a human cardiac-specific inhibitor of cell cycle that is cleaved by the proapoptotic Omi/HtrA2 protease during cell death Am J Physiol Heart Circ Physiol, August 1, 2009; 297(2): H643 - H653. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Radhakrishnan, I. M. Ayoub, and R. J. Gazmuri Activation of caspase-3 may not contribute to postresuscitation myocardial dysfunction Am J Physiol Heart Circ Physiol, April 1, 2009; 296(4): H1164 - H1174. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Tosaki and I. Edes The role of peroxiredoxins in ischemia-reperfusion-induced cardiac damage Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2586 - H2587. [Full Text] [PDF] |
||||
![]() |
V. P.M. van Empel, A. T.A. Bertrand, L. Hofstra, H. J. Crijns, P. A. Doevendans, and L. J. De Windt Myocyte apoptosis in heart failure Cardiovasc Res, July 1, 2005; 67(1): 21 - 29. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |